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Abstract Synovial fibroblasts from patients with osteoarthritis 
in culture produced parathyroid hormone-related peptide 
(PTHrP) on treatment with phorbol ester (TPA) in a dose- 
and time-dependent manner. The levels of PTHrP immunor- 
eactivity in the conditioned medium of synovial fibroblast 
cultures were measured using specific PTHrP antibody. The 
maximum production was obtained at a concentration of 10 -8 M 
and 24 h after TPA treatment. But sensitivity to TPA of synovial 
fibroblasts differed among four patients from slight to marked. 
PTHrP production was also induced with inflammatory cyto- 
kines, such as 1 nglml of IL-lcx, IL-113, IL-6 and TNF-~ and 
10 -6 M prostaglandin E2, after 24 h treatment. The expression 
of PTHrP was confirmed by reverse-transeriptase polymerase 
chain reaction. Since the synovial fibroblasts isolated from 
osteoarthritic patients produce high levels of IL-6 and IL-8, 
typical cytokines produced in synovial fibroblasts, production of 
PTHrP may provide new insight into the pathophysiology of 
joint disorder. 
© 1998 Federation of European Biochemical Societies. 
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endothelial cells in blood vessels, were demonstrated to ex- 
press PTHrP by immunohistochemistry [9]. However, it has 
not yet been determined whether PTHrP is actually produced 
in synovial cells established from synovial membrane in cul- 
ture. Synovial fibroblasts, abundant components of the syno- 
vial membrane, proliferate markedly in arthritis and cause 
hypertrophy. Then, synovial fibroblasts isolated from synovial 
membrane of osteoarthritis were established in culture, and 
examined for PTHrP production in the presence or absence 
of activating factors such as phorbol ester, inflammatory cy- 
tokines and prostaglandin E2 (PGE2). In this study we dem- 
onstrate that production of PTHrP was induced in synovial 
fibroblasts with not only phorbol ester TPA, but also inflam- 
matory cytokines and PGE2. PTHrP influences the prolifera- 
tion of lymphocytes [10], and the N-terminal peptide portion 
(1-34) acts as a stimulator of in vivo bone resorption when 
applied intermittently to neonatal mice [11]. Our findings sug- 
gested that PTHrP produced by synovial fibroblasts plays a 
novel role as a paracrine/autocrine factor in the pathophysi- 
ology of osteoarthritis. 
2. Materials and methods 
I. Introduction 
The parathyroid hormone-related peptide (PTHrP) was first 
identified as a tumor-derived peptide responsible for a syn- 
drome known as humoral hypercalcemia of malignancy 
[1,2]. Although the biological function of PTHrP is still un- 
clear, it is thought hat this peptide plays an important role in 
the development [3] and pathophysiology [4,5] of numerous 
diseases. Widespread abnormalities in endochondral ossifica- 
tion and skeletal development were shown in PTHrP-deficient 
mice [3,6]. Recently it has been reported that synovial fluids 
from patients with osteoarthritis and rheumatoid arthritis 
contain high levels of PTHrP [7]. Expression of PTHrP in 
normal and abnormal cartilage tissue from patients with os- 
teoarthritis or rheumatoid arthritis, using immunohistochem- 
istry and in situ hybridization, was also reported [8]. Further- 
more, many kinds of cells in arthral tissue, such as osteoclasts 
and osteoblasts of deteriorating bony tissue, synovial cells in 
the superficial ayer, macrophages in the deeper layer and 
*Corresponding author. Fax: (81) (3) 3579-4776. 
2.1. Patients 
Osteoarthritis was diagnosed and classified on the basis of radio- 
graphic findings. Radiographs of osteoarthritic patients howed joint- 
space narrowing, sclerotic hanges, and erosion of grade Ill. Synovial 
tissues were obtained from four female patients (age range 67 76) 
when they underwent the arthroplasty operation for severe inflamma- 
tory or destructive l sions in the knee. Informed consent was obtained 
from each patient. 
2.2. Isolation and culture of synovial fibroblasts 
The synovial cells were isolated according to the method of Takaya- 
nagi et al. [12]. In brief, the synovial tissue was dissected away, 
washed twice with RPMI 1640 (Gibco BRL, Gaithersburg, MD, 
USA), and finely minced. The minced tissue was incubated in 
RPM1 1640 containing 1mg/ml collagenase (Wako Pure Chemicals, 
Osaka, Japan) and 0.15 mg/ml DNase I (Sigma, St. Louis, MO, USA) 
and incubated with shaking for 90 min at 37°C. The cell suspension 
was filtered through a 70 lam cell strainer (Becton-Dickinson, Franklin 
Lakes, N J). The cell suspension (3ml) was layered on 4 ml of Ficoll/ 
Paque (Pharmacia Biotech, Uppsala, Sweden) and centrifuged at 
400×g for 30 min at 20°C. The interface layer was resuspended in 
4 volumes of RPMI 1640 and washed three times by centrifugation at 
250×g for 10 min. The cells were finally suspended in a-minimum 
essential medium (o~-MEM) (Irvine Scientific, Santa Ana, CA) con- 
taining 20% heat-inactivated horse serum (Gibco BRL, Gaithersburg, 
MD) and cultured in a 5% CO2 incubator. Medium was changed 
every 3 days. When cells reached confluence, those that dispersed after 
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agitating with 0.02% trypsin and 0.05% EDTA in Ca 2+- and Mg 2+- 
free phosphate-buffered saline (PBS) for 5 rain were transferred to 
new plastic dishes in a split ratio of 1:2 or 1:4. The culture medium 
was replaced two times each week. More than seven passaged cells (7 
population doubling levels, PDL) were used for subsequent experi- 
ments. This cell fraction consisted of only fibroblasts, with no den- 
dritic or monocytic ells. 
2.3. Treatment with cytokines and other stimulants 
The synovial fibroblasts at 7 12 PDL were treated with trypsin/ 
EDTA solution for 5 rain to detach them from dishes and collected 
by centrifugation at250 ×g for l0 min. The detached cells were plated 
onto 12 well multiwell dishes at 2× l0 s cells/well with 1.0 ml of c~- 
MEM containing 20% horse serum. When cells reached confluence, 
they were incubated with various concentrations of phorbol 12-myr- 
istate 13-acetate (TPA) (Sigma), 1 or 10 ng/ml of recombinant human 
cytokines uch as interleukin (IL)-10~, IL-I[3, IL-6 and tumor necrosis 
factor (TNF)-~ (Genzyme Diagnostics, Cambridge, MA, USA), and 
10 ~i or 10 -s M of PGE2 (Wako Pure Chemicals) for 24 h after 
replacement of the culture medium with c~-MEM supplemented with 
5% horse serum. The PTHrP level in the conditioned medium was 
measured irectly by immunoradiometric assay (IRMA). The amount 
of DNA in each well was measured by the method of Burton [13] after 
extraction with hot 5% perchloric acid. 
2.4. Measurement of PTHrP, L-6 and 1L-8 in the conditioned medium 
PTHrP concentrations in the conditioned medium was measured by 
two-site IRMA method (Allegro PTHrP, Nichols Institute Diagnos- 
tics, Capistrano, CA, USA) using two kinds of polyclonal antibodies 
against human PTHrP (1 86). The two-site IRMA method was per- 
formed with ~2Sl-polyclonal ntibody against N-terminal residues (1 
40) of human PTHrP and with biotin-polyclonal ntibody against C- 
terminal residues (6~72) of human PTHrP by the addition of avidin- 
coated beads. The sensitivity of this assay is 0.2 fmol/ml. The inter- 
assay coefficient of variation is 7.67 16.89%. Human intact PTH(I 
84), PTH fragment (1 34), N-terminal fragments of PTHrP (l~,0), 
and C-terminal fragment of PTHrP (109 141) were not detected. De- 
tails have been described previously [14]. Determination of human IL- 
6 and IL-8 was by enzyme linked immunoassay (ELISA), using Per- 
septive Biosystems (Framingham, MA, USA). The sensitivity of this 
assay is 1 pg/ml. 
2.5. Reverse transeriptase PCR (RT-PCR) 
RT reaction and PCR amplification were performed using the RNA 
LA PCR kit (Ver. 1.1, Takara Biomedicals, Osaka, Japan). 1 lag of 
total RNA from synovial fibroblasls (T-12 cells) at 10 PDL treated 
with stimulants for 24 h was hybridized to oligo dT-adaptor primer, 
and the RT reaction was carried out using AMV reverse transcriptase 
XL (Life Sciences, FL, USA) for 1 h at 42°C. The synthetic forward 
primer (5'-CTGGT TCAGC ATGGG AGGGTC-3') and the reverse 
primer (5'-GTTAG GGGAC CACCT CCGAGGT-Y) were designed 
to amplify a 231 bp fragment. The following PCR profile was used as 
described by Li et al. [15]: denaturation at 94°C for 60 s, reannealing 
at 60°C for 45 s, extension at 72°C for 60 s, 45 cycles. Amplified 
products were separated by electrophoresis on a 2.0%, agarose gel. 
GAPDH primers were used to control cDNA samples. 
3. Results 
3.1. PTHrP  production in synovial fibroblasts 
The synovial fibroblasts, T-2, T-12, T-17, and T-21 cells, 
established from synovial membrane of four patients with 
osteoarthritis were treated with various concentrations of 
phorbol ester TPA at confluence. Production of PTHrP in 
the culture medium was measured by the two-site IRMA 
method for human PTHrP (1-86). The production maximized 
at 10 -s M TPA treatment and then gradually decreased with 
increasing concentration in all cell strains except T-17 cells 
(Fig. 1). The induction of PTHrP with TPA differed among 
cell strains. T-17 cells were scarcely induced by the treatment, 
whereas T-12 cells were markedly induced. These treatments 
did not affect cell morphology or viability. Since the fibro- 
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blasts were subcultured more than seven times for 6-8 weeks, 
dendritic cells, monocytes, and other blood cells derived from 
synovial membrane disappeared, and only the flbroblasts re- 
mained. Further investigations were performed using T-12 
cells. Production of PTHrP was induced 6 h after treatment, 
and increased in a t ime-dependent manner up to 24 h. Incu- 
bation beyond this did not induce production further (Fig. 2). 
Induction did not occur under low serum conditions, as in ~- 
MEM supplemented with 0.2% horse serum (data not shown). 
Culture medium alone did not react with the antibody used in 
this assay system. 
3.2. Cytokine-induced PTHrP  
Whether inf lammatory cytokines such as IL-lc~, IL-I[3, IL- 
6, and TNF-c~ induce PTHrP in synovial fibroblasts was in- 
vestigated. Both IE-lcx and IL-I[3 induced PTHrP in a dose- 
dependent manner. The amount of PTHrP induced by IL-lc~ 
was equal to that by 10 9 M TPA. But IL-6 and TNF-a  
slightly enhanced the production. High concentrations of 
IL-6 and TNF-c~ may be required for efficient induction. 
PGE~, which has a strong inf lammatory effect and is generally 
produced in inf lammatory tissues, also induced PTHrP in a 
dose-dependent manner  (Fig. 3). Expression of mRNA of 
PTHrP in the fibroblasts was confirmed by RT-PCR. As 
shown in Fig. 4, untreated cells also expressed the mRNA,  
although TPA or IE-lc~ treatment only slightly enhanced the 
mRNA level. Forskolin and TNF-c~ did not enhance PTHrP 
expression. The level of GAPDH expression did not vary 
among samples. 
These results suggest hat synovial fibroblasts from patients 
with osteoarthrit is produce PTHrP during inf lammation proc- 
ess. 
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Fig. 1. TPA-induced PTHrP production in synovial fibroblasts. 
Synovial fibroblasts established from four patients with osteoarthri- 
tis in culture at 7-12 PDL were plated to 12 well multiwell plates. 
Confluent cells were incubated with various concentrations of phor- 
bol ester TPA in 0.5 ml of c~-MEM supplemented with 5% horse se- 
rum for 24 h. The PTHrP released in the conditioned medium was 
directly assayed by the two-site IRMA method for human PTHrP 
(186). The values represent the mean+S.E.M. (n=3). The DNA 
content per well was 10,5--19.5 gg. White bars: T-2 ceils (9 PDL); 
black bars: T-12 cells (12 PDL); horizontally hatched bars: T-17 
cells (7 PDL); diagonally hatched bars: T-21 cells (8 PDL). 
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Fig. 2. Time-dependent increase of PTHrP with TPA treatment in 
synovial fibroblasts. Confluent T-J2 ceils were incubated with I0 -s 
M TPA for the indicated tfines. The amount of PTHrP released in 
the medium was measured as described in Fig. ]. 
3.3. Production of IL-6 and IL-8 by synovial fibroblasts 
To identify fibroblast phenotype, production of IL-6 and 
IL-8 in conditioned medium (see Fig. 1) was measured by 
ELISA. These cells produced detectable amounts of IL-6 
and IL-8 without any stimulants. However, the production 
was markedly induced with TPA treatment. The induction 
rate for IL-6 and IL-8 was more than that for PTHrP, with 
the same tendency among three cell strains (Table 1). T-12 
cells were tremendously sensitive to TPA treatment in com- 
parison with T-2 and T-17 cells. In T-17 cells, PTHrP produc- 
tion was not induced with TPA treatment, but 1L-6 and IL-8 
productions were induced at the same level as in T-2 cells. T- 
12 cells also produced a large quantity of prostaglandin E2 
(data not shown) as reported previously [16]. IL-113 and TNF-  
c~ were not detected (data not shown). 
Table 1 
IL-6 and IL-8 production in synovial fibroblasts 
Cell strain Treatment with 
TPA (M) 
Cytokine production (pg/ml) 
IL-6 IL-8 
T-2 0 683+7 1651 +87 
10 ~ 2678 + 173 41804 + 4021 
10 '~ 9131 +503 81547_ + 12323 
10 7 7932 + 405 53407 _+ 4504 
10 !; 7703 _+ 978 44618 _+ 5615 
10 -~ 6050 ~ 40438 ~L 
T-17 0 180_+21 251 _+ 56 
10 " 631 _+ 166 1483_+859 
l0 ~ 1574 _+ 100 12056 _+ 3398 
10 7 1530_+ 137 7998_+530 
10 -~ 1244 _+ 122 5553 _+ 3309 
10 ~' 1459_+217 694P 
T-21 0 501 _+ 28 180 _+ 22 
10 !~ 1570 _+ 400 2456 _+ 782 
10 s 1912+95 10138_+3964 
10 7 2183_+94 7839_+590 
10 ~ 1948 _+ 94 3449 _+ 567 
l0 r, 2130_+ 117 3848 ~ 
The levels of IL-6 and IL-8 released in the medium described for Fig. 
1 were measured by EIA. Values represent the mean + S.E.M. (n -- 3). 
~'Indicates the value from one sample. 
4. Discussion 
This study presents the first finding of PTHrP production 
by synovial fibroblasts from patients with osteoarthritis in 
vitro. The accumulation of PTHrP in synovial fluid has 
been reported by Kohno et al. [7] and Okano et al. [8]. The 
synovial fluid level of the C-terminal region of PTHrP (C- 
PTHrP) was markedly higher in rheumatoid arthritis com- 
pared with control and osteoarthritis groups, while no differ- 
ences in circulatory C-PTHrP in serum were present among 
the three groups. In contrast, the synovial fluid level of the N- 
terminal region of PTHrP (N-PTHrP), which has a stimula- 
tory effect on bone resorption [17], was marginally higher in 
osteoarthritis. Moreover, immunoreactivity o PTHrP (38 64, 
mid-portion) antibody was more frequently identified in os- 
teoarthritic cartilage (specimens) than rheumatoid arthritic 
specimens and control subjects [8]. PTHrP produced in arthral 
tissue likely has important roles in osteoarthritis and subse- 
quent cartilage degeneration and bone destruction. In this 
study we found that inflammatory cytokines and PGE2 re- 
ported in synovial fluid [16] induced PTHrP production by 
synovial fibroblasts. Our results suggested PTHrP production 
by synovial fibroblasts contributes to the inflammatory proc- 
ess in arthral tissue. Synovial fibroblasts in culture did not 
decrease PTHrP production during passage from 7 PDL to 
12 PDL, but four strains donated by different individuals 
produced levels of PTHrP that varied widely. Since we used 
the synovial membranes of surgical waste, the inflammation 
was chronic, not acute, as shown by the low basal production 
level (Fig. 1, Table 1). The IL-6 and IL-8 productions in 
synovial fibroblasts [18] were higher than in human skin fi- 
broblasts al the basal level (data not shown), thus the fibro- 
blasts established here appear to maintain the characteristics 
of synovial fibroblasts. Interestingly, these cells produced M- 
CSF (macrophage colony stimulating factor) and PGE2, and 
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Fig. 3. Cytokine- and PGE2-induced PTHrP production by synovial 
fibroblasts. Confluent T-12 cells were incubated with 1 ng/ml (black 
bars) or 10 ng/ml (hatched bars) of IL-let, IL-I~, IL-6 and TNF-0c 
for 24 h. The PTHrP released in the conditioned medium was meas- 
ured as described in Fig. 1. In the case of PGE2, 10 ~' M (black 
bar) or 10 -G M (hatched bar) PGE2 was used. White bars: un- 
treated control cells. 
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Fig. 4. Expression of PTHrP in T-12 cells as assessed by RT-PCR. 
An ethidium bromide-stained 2% agarose gel is shown after electro- 
phoretic separation of RT-PCR products. Confluent T-12 cells were 
incubated with 10 8 M TPA (lanes 2, 7), 10 5 M forskolin (lanes 3, 
8), 10 ng/ml IL-lo~ (lanes 4, 9) and 10 ng/ml TNF-~ (lanes 5, 10) 
for 24 h. Untreated control cells are shown in lanes 1, 6. Total 
RNA was used for RT-PCR analysis. Lanes 1 5 show PTHrP ex- 
pression (231 bp), and lanes 6-10 show GAPDH expression. Lane 
M: DNA size markers. 
ester TPA, a protein kinase C activator, induced PTHrP pro- 
duction, as reported in rat articular cartilage [19] and mam- 
mary epithelial cells [20], but 10 8 M phorbol ester TPA only 
slightly changed the level of PTHrP mRNA. In our experi- 
ment, the level of PTHrP mRNA in RT-PCR changed little 
on addition of TPA or IL-lc¢, which contrasts with the en- 
hancement in the conditioned medium. It is difficult to com- 
pare PTHrP mRNA levels among samples quantitatively by 
the RT-PCR analysis used here. 
Our findings suggest hat PTHrP production is induced in 
synovial fibroblasts in the inflammatory state, at the protein 
and mRNA level. 
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